Wegovy (Semaglutide): Complete 2026 Guide
Pricing, coupons, insurance coverage, and access pathways for the FDA-approved GLP-1 for chronic weight management. Pill and pen compared. Verified monthly.
Wegovy (semaglutide) is Novo Nordisk's FDA-approved GLP-1 for chronic weight management. List price is about $1,349 per 28-day supply. Commercially insured patients can pay as low as $25 per month via the Savings Card. Cash-pay patients have two formulations: the once-daily Wegovy pill at $149 per month for the 1.5mg or 4mg starter doses, or the weekly Wegovy pen at $199 per month for new patients (first 2 fills) then $349 per month. Medicare Part D already covers Wegovy for cardiovascular event risk reduction in eligible patients; full weight-loss coverage begins rolling out in 2026.
What is Wegovy?
Wegovy is the brand name for semaglutide when prescribed for chronic weight management. It comes in two FDA-approved formulations: a weekly subcutaneous pen (0.25mg through 2.4mg, plus the higher-dose 7.2mg Wegovy HD) and a once-daily oral tablet (1.5mg, 4mg, 9mg, 25mg). The pill is the only FDA-approved semaglutide tablet for weight loss.
Ozempic is the same molecule marketed for type 2 diabetes. Rybelsus is oral semaglutide for diabetes. The difference between these products comes down to FDA-approved indication and insurance coverage rules, not active ingredient.
Pricing snapshot
From $25 per month with insurance and a Savings Card, up to $1,349 per month at list price. Pill starter doses are currently the cheapest legitimate cash-pay path.
Pill vs pen, at a glance
Both formulations use the same active ingredient. The tradeoff is convenience, efficacy, and cost.
Wegovy pill
- Only FDA-approved oral semaglutide for weight loss
- Doses: 1.5mg, 4mg, 9mg, 25mg
- Mean weight loss 13.6 percent at 64 to 72 weeks in trials
- Cash pay: $149/mo starter doses, $299/mo high doses
Wegovy pen
- Established formulation, most clinical data
- Doses: 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, plus Wegovy HD 7.2mg
- Mean weight loss 18.8 percent at 64 to 72 weeks in trials
- Cash pay: $199/mo new-patient intro, $349/mo standard, $399/mo HD
For the full comparison including efficacy trial data and who should choose which, see the Wegovy pill vs injection guide.
Explore the guide
Three dedicated pages cover the details you need: every active coupon, the full cost breakdown for pill and pen, and patient reviews.
Recent pricing news
Four events in the last year reshaped the Wegovy pricing landscape.
- February 23, 2026
Wegovy pill self-pay pricing expanded
Novo Nordisk expanded the Wegovy pill self-pay program. Current promotional pricing: $149/month for 1.5mg and 4mg doses through Aug 31, 2026 (then $199/month for 4mg). 9mg and 25mg doses at $299/month. This is the only FDA-approved semaglutide tablet for weight loss.
- November 6, 2025In progress
Most-Favored-Nation (MFN) pricing framework announced
Federal framework tying U.S. GLP-1 prices to lowest prices paid in comparable countries. Expected impact: Wegovy may be available at lower prices on a government discount platform launching early-to-mid 2026. Medicare copays capped at $50/month for eligible enrollees.
Status: Announced, implementation in progress.
- March 1, 2025
NovoCare Self-Pay launched at $499
Novo launched direct-to-consumer self-pay program initially at $499/month for the pen. Prices have since adjusted down for new-patient introductory periods ($199/month for 2 fills).
- Invalid DateIn progress
Potential generic semaglutide availability
Wegovy patent expires in 2026 per WW reporting. Generic semaglutide manufacturers may enter the market, potentially significantly lowering prices. No generic currently available.
Status: Anticipated but not confirmed. Verify monthly.
Frequently asked
The top questions we see about Wegovy access and cost. Full FAQ on the coupon page.
Pricing verified against Novo Nordisk's official wegovy.com and novocare.com pages, cross-referenced with GoodRx, Weight Watchers, Walgreens, and SingleCare. We do not accept payment for inclusion in any comparison. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Quarterly re-verification scheduled.